Myovant Sciences to Host Third Fiscal Quarter 2020 Earnings Conference Call at 8:30 a.m. Eastern Time on February 11, 2021

Rhea-AI Summary

Myovant Sciences (NYSE: MYOV) announced a webcast and conference call on February 11, 2021, at 8:30 a.m. ET, to discuss its Q3 2020 financial results for the period ending December 31, 2020. Investors can access the live event via Myovant’s investor relations page. The company currently has one FDA-approved medicine, ORGOVYX™, and is awaiting regulatory review for its lead product candidate for uterine fibroids. Myovant aims to redefine care for men and women with innovative treatments.

Positive

• One FDA-approved medicine, ORGOVYX™, for prostate cancer.
• Lead product candidate under regulatory review for uterine fibroids.

Negative

• None.

BASEL, Switzerland, Jan. 29, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced it will host a webcast and conference call to discuss corporate updates and financial results for its third fiscal quarter 2020, ended December 31, 2020. The webcast and conference call will be held at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time on February 11, 2021.

Investors and the general public may access a live webcast of the call by visiting the investor relations page of Myovant’s website at investors.myovant.com. Institutional investors and analysts may also participate in the conference call by dialing 1-800-532-3746 in the U.S. or +1-470-495-9166 from outside the U.S.

A replay of the webcast, along with the earnings press release and presentation slides, will be archived on Myovant’s investor relations website.

About Myovant Sciences 
Myovant Sciences aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy. We have one FDA-approved medicine, ORGOVYX™ (relugolix), for adult patients with advanced prostate cancer. Our lead product candidate, relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg), is under regulatory review in Europe and the U.S. for women with uterine fibroids and is under development for women with endometriosis. We are also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, which has completed a Phase 2a study for female infertility as part of assisted reproduction. Sumitovant Biopharma, Ltd., a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., is our majority shareholder. For more information, please visit our website at www.myovant.com. Follow @Myovant on Twitter and LinkedIn.

Investor Contact:
Ryan Crowe
Vice President, Investor Relations
Myovant Sciences, Inc.
+1 (650) 781-9106
investors@myovant.com

Media Contact:
Albert Liao 
Director, Corporate Communications
Myovant Sciences, Inc.
+1 (650) 410-3055
media@myovant.com

FAQ

What are the financial results Myovant will discuss on February 11, 2021?

Myovant will discuss its Q3 2020 financial results during the conference call.

What is the significance of the FDA-approved drug ORGOVYX™?

ORGOVYX™ is Myovant's FDA-approved treatment for advanced prostate cancer, representing a key revenue stream.

When does Myovant plan to release its earnings report?

The earnings report will be discussed during the webcast on February 11, 2021.

What is Myovant's lead product candidate?

Myovant's lead product candidate is a combination tablet under review for uterine fibroids and endometriosis.